Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd lifted its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) by 1,910.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 74,255 shares of the company’s stock after acquiring an additional 70,561 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Keros Therapeutics were worth $1,175,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. KBC Group NV boosted its holdings in Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after buying an additional 280 shares during the last quarter. LMR Partners LLP acquired a new stake in Keros Therapeutics during the third quarter worth about $213,000. Victory Capital Management Inc. acquired a new stake in Keros Therapeutics during the third quarter worth about $216,000. Finally, Point72 Asia Singapore Pte. Ltd. raised its position in Keros Therapeutics by 36.7% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company’s stock valued at $223,000 after acquiring an additional 1,033 shares in the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Stock Up 0.4 %

KROS stock opened at $10.94 on Thursday. Keros Therapeutics, Inc. has a 52 week low of $9.77 and a 52 week high of $73.00. The firm has a 50-day simple moving average of $12.76 and a 200-day simple moving average of $39.99. The stock has a market capitalization of $443.15 million, a P/E ratio of -2.10 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $3.04 million for the quarter, compared to analysts’ expectations of $37.32 million. On average, analysts expect that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on KROS. Scotiabank lowered their price objective on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a research report on Thursday, January 16th. Jefferies Financial Group began coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating on the stock. Oppenheimer cut their price objective on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a report on Thursday, January 16th. HC Wainwright lowered their target price on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Finally, Guggenheim restated a “neutral” rating on shares of Keros Therapeutics in a research report on Friday, January 17th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Keros Therapeutics has an average rating of “Moderate Buy” and an average target price of $52.56.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.